Sagimet Biosciences Inc. (SGMT) — Financial statements
Income statement, balance sheet, and cash flow for Sagimet Biosciences Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00↓100.0% | 2 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 0.00 | 0.00↓100.0% | 2 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 39↑1.6% | 38↑94.4% | 20↓20.6% | 25↑28.8% | 19 | |
| General & Administrative Expenses | 18↑11.4% | 16↑23.5% | 13↑111.3% | 6↑40.1% | 4 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 18↑11.4% | 16↑23.5% | 13↑111.3% | 6↑40.1% | 4 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 57↑4.5% | 54↑66.3% | 33↑5.4% | 31↑30.9% | 24 | |
| Total Costs & Expenses | 57↑4.5% | 54↑66.3% | 33↑5.4% | 31↑30.9% | 24 | |
| Operating Results | ||||||
| Operating Income | -57↓4.5% | -54↓77.1% | -31↑1.0% | -31↓30.9% | -24 | |
| Depreciation & Amortization | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| EBITDA | -57↓24.8% | -46↓48.2% | -31↑1.0% | -31↓30.9% | -24 | |
| EBIT | -57↓24.8% | -46↓48.2% | -31↑1.0% | -31↓30.9% | -24 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.00 | 0.00↓100.0% | 3↑417.2% | 0.55↑2026.9% | 0.03 | |
| Interest Income | 0.00 | 0.00↓100.0% | 3↑417.2% | 0.55↑2026.9% | 0.03 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00↑100.0% | -9 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | 6↓34.2% | 9↑210.3% | 3↑415.1% | 0.56↑176.9% | -0.72 | |
| Income Before Tax | -51↓12.0% | -46↓63.5% | -28↑8.6% | -30↓24.8% | -24 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -51↓12.0% | -46↓63.5% | -28↑8.6% | -30↓24.8% | -24 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -51↓12.0% | -46↓63.5% | -28↑8.6% | -30↓24.8% | -24 | |
| Bottom-Line Net Income | -51↓12.0% | -46↓63.5% | -28↑8.6% | -30↓24.8% | -24 | |
| EPS (Basic) | -1.58↓9.0% | -1.45↑5.2% | -1.53↓10.9% | -1.38↓25.5% | -1.10 | |
| EPS (Diluted) | -1.58↓9.0% | -1.45↑5.2% | -1.53↓10.9% | -1.38↓25.5% | -1.10 | |
| Weighted Average Shares | 32↑3.2% | 31↑72.3% | 18↓17.9% | 22↑0.0% | 22 | |
| Weighted Average Diluted Shares | 32↑3.2% | 31↑72.3% | 18↓17.9% | 22↑0.0% | 22 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.